First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer

导出原文传递

翻译打印收藏纠错

作者： Zheng, Jing ^[1] ; Shen, Lisha ^[2] ; Jiang, Nan ; Zhu, Yanping ; Wu, Lihua ; Cao, He ; Sun, Wenjia ; Zhou, Jianya ; Zhou, Jianying

作者单位： Zhejiang Univ, Affiliated Hosp 1, Coll Med, Thorac Dis Ctr, 79 Qingchun Rd, Hangzhou 310003 ^[1] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Res Ctr Clin Pharm, Hangzhou, Peoples R China ^[2]

关键词 Epidermal growth factor receptor ES-072 Non-small-cell lung cancer Tyrosine kinase inhibitor T790M

发布时间 2021-04-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Clinical lung cancer

2020年21卷6期

509-+页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer

Clinical lung cancer

相似文献

Clinical lung cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer

Clinical lung cancer

相似文献

Clinical lung cancer

相关期刊

检索历史清除